Subject Category: Stem cells and regenerative medicine
Citation: Experimental & Molecular Medicine (2014) 46, e110; doi:10.1038/emm.2014.49
Published online 22 August 2014
Therapeutic effect of hepatocyte growth factor-secreting mesenchymal stem cells in a rat model of liver fibrosis
1Department of Biochemistry, Ajou University School of Medicine, Suwon, Republic of Korea
2Chronic Inflammatory Disease Research Center, Ajou University School of Medicine, Suwon, Republic of Korea
3Department of Anatomy, Ajou University School of Medicine, Suwon, Republic of Korea
4Center for Cell Death Regulating Biodrug, Ajou University School of Medicine, Suwon, Republic of Korea
5Department of General Surgery, Ajou University School of Medicine, Suwon, Republic of Korea
Correspondence: Professor H Suh-Kim, Department of Anatomy, Ajou University School of Medicine, Youngtong-gu, Woncheon-dong, San 5, Suwon 443-749, Republic of Korea. E-mail: [email protected]; Professor J-H Lee, Department of Biochemistry, Ajou University School of Medicine, Yeongtong-gu, Wonchen-dong, San 5, Suwon 443-721, Republic of Korea. E-mail: [email protected]
6These two authors contributed equally to this work.
Received 11 May 2014; Accepted 8 June 2014
Top of page
Abstract
Bone marrow-derived mesenchymal stromal cells (MSCs) have been reported to be beneficial for the treatment of liver fibrosis. Here, we investigated the use of genetically engineered MSCs that overexpress hepatocyte growth factor (HGF) as a means to improve their therapeutic effect in liver fibrosis. Liver fibrosis was induced by intraperitoneal injection of dimethylnitrosamine. HGF-secreting MSCs (MSCs/HGF) were prepared by transducing MSCs with an adenovirus carrying HGF-encoding cDNA. MSCs or MSCs/HGF were injected directly into the spleen of fibrotic rats. Tissue fibrosis was assessed by histological analysis 12 days after stem cell injection. Although treatment with MSCs reduced fibrosis, treatment with MSCs/HGF produced a more significant reduction and was associated with elevated HGF levels in the portal vein. Collagen levels in the liver extract were decreased after MSC/HGF therapy, suggesting recovery from fibrosis. Furthermore, liver function was improved in animals receiving MSCs/HGF, indicating that MSC/HGF therapy resulted not only in reduction of liver fibrosis but also in improvement of hepatocyte function. Assessment of cell and biochemical parameters revealed that mRNA levels of the fibrogenic cytokines PDGF-bb and TGF-β1 were significantly decreased after MSC/HGF therapy. Subsequent to the decrease in collagen, expression of matrix metalloprotease-9 (MMP-9), MMP-13, MMP-14 and urokinase-type plasminogen activator was augmented following MSC/HGF, whereas tissue inhibitor of metalloprotease-1 (TIMP-1) expression was reduced. In conclusion, therapy with MSCs/HGF resulted in an improved therapeutic effect compared with MSCs alone, probably because of the anti-fibrotic activity of HGF. Thus, MSC/HGF represents a promising approach toward a cell therapy for liver fibrosis.